Comment Deadline: FDA Patient-Focused Drug Development on Chronic Pain

The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on “Patient-Focused Drug Development for Chronic Pain.” The public meeting will provide patients (including adult and pediatric patients) with an opportunity to present to FDA their perspectives on the impacts of chronic pain, views on treatment approaches for chronic pain, and challenges or barriers to accessing treatments. This meeting will provide FDA the opportunity to better understand patients' perspectives on the impacts of chronic pain, patient views on treatment approaches for chronic pain, and challenges or barriers to accessing treatments. 

Members of the public may submit comments by mail or at Regulations.gov. More information is available at the Federal Register.

Event Date
Monday, September 10, 2018 - 5:00pm
Topics
Neuroscience